ORGO on Nasdaq
Organogenesis Holdings Inc.
American pharmaceutical preparations company based in Canton. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with TARO Pharmaceuticals, Hutchison China Meditech or Catalyst Pharmaceuticals, or pick any stock.
- TickerORGO on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersCanton, United States2
- Incorporated inDE3
- Business address85 Dan Road, Canton, Ma 020213
- Filer categoryAccelerated filer3
- Legal formCorporation2
- LEI549300RLC2O821TU69412
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 71867342
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
7.9%Operating margin4
6.6%Net margin4
17.0%Revenue growth, 20254
12.3%Return on equity4
-$24.5MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 100% of the revenue Organogenesis Holdings Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $433.1M | $482.0M | $563.0M |
| Grant | $0 | $0 | $1.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development8¢$44.5M
- Selling, general and admin58¢$326.2M
- Other costs26¢$146.4M
- Income tax2¢$9.9M
- Profit7¢$37.0M
Out of $564.2M in revenue.4
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $564.2M | $482.0M | $433.1M |
| Cost of goods sold | $137.5M | $115.7M | $106.5M |
| Selling, general and administrative | $326.2M | $294.5M | $269.8M |
| Research and development | $44.5M | $50.3M | $44.4M |
| Write-down to fair value for asset held for sale | $11.2M | ||
| Impairment of property and construction | $18.8M | ||
| Write-down of capitalized internal-use software costs | $4.0M | ||
| Total operating expenses | $519.5M | $483.3M | $420.6M |
| Income (loss) from operations | $44.7M | -$1.3M | $12.5M |
| Interest income (expense), net | $2.3M | -$1.5M | -$2.2M |
| Other income (expense), net | -$5.0K | $20.0K | $57.0K |
| Total other income (expense), net | $2.3M | -$1.5M | -$2.1M |
| Net income (loss) before income taxes | $47.0M | -$2.8M | $10.4M |
| Income tax benefit (expense) | -$9.9M | $3.7M | -$5.4M |
| Net income (loss) and comprehensive income (loss) | $37.0M | $861.0K | $4.9M |
| Accretion of redeemable convertible preferred stock to redemption value | -$540.0K | -$412.0K | |
| Cumulative dividend on redeemable convertible preferred stock | -$10.8M | -$1.4M | |
| Undistributed earnings allocated to participating redeemable convertible preferred stock | -$5.6M | ||
| Net income (loss) attributable to common stockholders - basic | $20.0M | -$937.0K | $4.9M |
| Net income (loss) attributable to common stockholders - diluted | $20.0M | -$937.0K | $4.9M |
| Basic | $0.16 | -$0.01 | $0.04 |
| Diluted | $0.15 | -$0.01 | $0.04 |
| Basic | 126.7M shares | 131.7M shares | 131.2M shares |
| Diluted | 130.2M shares | 131.7M shares | 132.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $93.7M | $135.6M | ||
| Restricted cash | $652.0K | $580.0K | ||
| Accounts receivable, net of allowance for credit losses of $17,467 and $9,576 | $217.5M | $109.9M | ||
| Inventories, net | $29.6M | $26.2M | ||
| Asset held for sale (Note 8) | $2.4M | |||
| Prepaid expenses and other current assets | $18.4M | $13.7M | ||
| Total current assets | $362.2M | $285.9M | ||
| Property and equipment, net | $103.7M | $89.1M | ||
| Intangible assets, net | $9.1M | $12.5M | ||
| Goodwill | $28.8M | $28.8M | ||
| Operating lease right-of-use assets, net | $55.7M | $37.1M | ||
| Deferred tax asset, net | $30.0M | $39.5M | ||
| Other assets | $9.2M | $5.0M | ||
| Total assets | $598.7M | $497.9M | ||
| Current portion of finance lease obligations | $9.4M | $1.2M | ||
| Current portion of operating lease obligations - related party | $4.3M | $3.7M | ||
| Current portion of operating lease obligations | $4.9M | $4.3M | ||
| Accounts payable | $31.9M | $28.9M | ||
| Accrued expenses and other current liabilities | $49.5M | $39.5M | ||
| Total current liabilities | $100.1M | $77.5M | ||
| Finance lease obligations, net of current portion | $12.8M | $718.0K | ||
| Operating lease obligations, net of current portion - related party | $28.2M | $8.3M | ||
| Operating lease obligations, net of current portion | $22.5M | $25.2M | ||
| Other liabilities | $1.2M | $894.0K | ||
| Total liabilities | $164.8M | $112.6M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $142,217 and $131,387 at December 31, 2025 and 2024, respectively. | $133.8M | $122.4M | ||
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,680,424 and 126,458,784 shares issued; 126,951,876 and 125,730,236 shares outstanding at December 31, 2025 and 2024, respectively | $13.0K | $13.0K | ||
| Additional paid-in capital | $303.2M | $303.0M | ||
| Accumulated deficit | -$3.1M | -$40.1M | ||
| Total stockholders' equity | $300.1M | $262.9M | $278.7M | $265.7M |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $598.7M | $497.9M | ||
| Allowance for credit losses | $16.1M | $9.6M | ||
| Series A redeemable convertible preferred stock, par value | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, shares issued | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, liquidation preference | $142.2M | $131.4M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 870.0K shares | 870.0K shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued | 127.7M shares | 126.5M shares | ||
| Common stock, shares outstanding | 127.0M shares | 125.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $93.7M | $135.6M | ||
| Restricted cash | $652.0K | $580.0K | ||
| Accounts receivable, net of allowance for credit losses of $17,467 and $9,576 | $217.5M | $109.9M | ||
| Inventories, net | $29.6M | $26.2M | ||
| Asset held for sale (Note 8) | $2.4M | |||
| Prepaid expenses and other current assets | $18.4M | $13.7M | ||
| Total current assets | $362.2M | $285.9M | ||
| Property and equipment, net | $103.7M | $89.1M | ||
| Intangible assets, net | $9.1M | $12.5M | ||
| Goodwill | $28.8M | $28.8M | ||
| Operating lease right-of-use assets, net | $55.7M | $37.1M | ||
| Deferred tax asset, net | $30.0M | $39.5M | ||
| Other assets | $9.2M | $5.0M | ||
| Total assets | $598.7M | $497.9M | ||
| Current portion of finance lease obligations | $9.4M | $1.2M | ||
| Current portion of operating lease obligations - related party | $4.3M | $3.7M | ||
| Current portion of operating lease obligations | $4.9M | $4.3M | ||
| Accounts payable | $31.9M | $28.9M | ||
| Accrued expenses and other current liabilities | $49.5M | $39.5M | ||
| Total current liabilities | $100.1M | $77.5M | ||
| Finance lease obligations, net of current portion | $12.8M | $718.0K | ||
| Operating lease obligations, net of current portion - related party | $28.2M | $8.3M | ||
| Operating lease obligations, net of current portion | $22.5M | $25.2M | ||
| Other liabilities | $1.2M | $894.0K | ||
| Total liabilities | $164.8M | $112.6M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $142,217 and $131,387 at December 31, 2025 and 2024, respectively. | $133.8M | $122.4M | ||
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,680,424 and 126,458,784 shares issued; 126,951,876 and 125,730,236 shares outstanding at December 31, 2025 and 2024, respectively | $13.0K | $13.0K | ||
| Additional paid-in capital | $303.2M | $303.0M | ||
| Accumulated deficit | -$3.1M | -$40.1M | ||
| Total stockholders' equity | $300.1M | $262.9M | $278.7M | $265.7M |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $598.7M | $497.9M | ||
| Allowance for credit losses | $16.1M | $9.6M | ||
| Series A redeemable convertible preferred stock, par value | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, shares issued | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding | 130.0K shares | 130.0K shares | ||
| Series A redeemable convertible preferred stock, liquidation preference | $142.2M | $131.4M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 870.0K shares | 870.0K shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued | 127.7M shares | 126.5M shares | ||
| Common stock, shares outstanding | 127.0M shares | 125.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $37.0M | $861.0K | $4.9M |
| Depreciation and amortization | $15.3M | $13.6M | $10.4M |
| Amortization of intangible assets | $3.3M | $3.4M | $4.9M |
| Reduction in the carrying value of right-of-use assets | $8.3M | $8.3M | $8.1M |
| Non-cash interest expense | $375.0K | $394.0K | $427.0K |
| Deferred interest expense | $305.0K | $490.0K | |
| Deferred tax expense (benefit) | $9.5M | -$10.7M | $2.0M |
| Loss on disposal of property and equipment | $188.0K | $1.1M | $235.0K |
| Loss on lease termination | $559.0K | ||
| Loss on extinguishment of term loan | $215.0K | ||
| Provision recorded for credit losses | $8.2M | $3.9M | $1.3M |
| Adjustment for excess and obsolete inventories | $15.4M | $8.2M | $6.6M |
| Stock-based compensation | $13.3M | $10.6M | $9.0M |
| Write-down to fair value for asset held for sale (Note 8) | $11.2M | ||
| Impairment of property and construction | $18.8M | ||
| Write down of capitalized internal-use software costs (Note 8) | $4.0M | ||
| Accounts receivable | -$115.8M | -$31.8M | $5.5M |
| Inventories | -$17.9M | -$6.2M | -$8.2M |
| Prepaid expenses and other current and other assets | -$183.0K | -$2.5M | -$10.1M |
| Operating leases | -$8.5M | -$14.1M | -$8.4M |
| Accounts payable | -$528.0K | -$2.4M | -$108.0K |
| Accrued expenses and other current liabilities | $10.4M | $9.2M | $3.1M |
| Other liabilities | $158.0K | -$1.1M | $91.0K |
| Net cash provided by (used in) operating activities | -$10.3M | $14.2M | $30.9M |
| Purchases of property and equipment | -$14.2M | -$10.0M | -$24.4M |
| Net cash used in investing activities | -$14.2M | -$10.0M | -$24.4M |
| Construction of landlord assets, net of tenant allowance | -$14.5M | ||
| Term loan repayments under the 2021 Credit Agreement | -$66.6M | -$4.7M | |
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | $120.7M | ||
| Payments for the repurchase of common stock | -$25.5M | ||
| Principal repayments of finance lease obligations | -$1.2M | -$1.1M | -$485.0K |
| Proceeds from the exercise of stock options | $157.0K | $1.2M | |
| Payments of withholding taxes in connection with RSUs vesting | -$1.9M | -$1.2M | -$332.0K |
| Net cash provided by (used in) financing activities | -$17.4M | $27.6M | -$5.5M |
| Change in cash, cash equivalents and restricted cash | -$41.8M | $31.8M | $1.0M |
| Cash paid for interest | $5.0M | $5.4M | |
| Cash paid for income taxes | $5.3M | $7.0M | $3.1M |
| Cumulative effect adjustment for adoption of ASU No. 2016-13 | $615.0K | ||
| Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $715.0K | -$432.0K | $841.0K |
| Right-of-use assets obtained through operating lease obligations | $27.0M | $5.1M | $5.9M |
| Right-of-use assets obtained through finance lease obligations | $21.5M | $3.5M | |
| Redeemable convertible preferred stock issuance costs included in accrued expenses | $67.0K | ||
| Prepaid rent reclassified to right-of-use assets | $230.0K | ||
| Landlord asset additions included in accounts payable and other liabilities, net of tenant allowances | $2.7M | ||
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | $11.4M | $1.8M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Organogenesis Holdings Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
20202025
- Chief executive officerDavid F. Burgstahler Dec 12, 2018 to Dec 12, 201813
- Chief executive officerGary S. Gillheeney Dec 12, 2018 to now14
- ChairThompson Dean Dec 12, 2018 to Dec 12, 201813
- PresidentDavid F. Burgstahler Dec 12, 2018 to Dec 12, 201813
- PresidentGary S. Gillheeney Dec 12, 2018 to now14
- Chief financial officerHenry Hagopian Iii. Aug 25, 2020 to Jan 15, 202115
- Chief financial officerTimothy M. Cunningham Dec 12, 2018 to Apr 24, 202016
- Chief financial officerJohn Cafasso Oct 7, 2016 to Oct 7, 201617
- Chief operating officerPatrick Bilbo Dec 12, 2018 to now18
Board members and other officers (32)
- Chief Accounting OfficerPatrick McGuire Feb 27, 2026 to now19
- Vice President, StrategyRobert Cavorsi Apr 29, 2024 to now20
- Chief Admin. and Legal OfficerLori Freedman Apr 4, 2023 to now21
- OfficerDavid F. Burgstahler Nov 1, 2018 to Nov 1, 201822
- OfficerThompson Dean Nov 1, 2018 to Nov 1, 201822
- VP Health Policy & ContractingAntonio S. Montecalvo Dec 12, 2018 to now23
- Chief Commercial OfficerBrian Grow Dec 12, 2018 to now24
- Exec. VP, Strat. & Mkt Dev.Howard Walthall Dec 12, 2018 to Dec 12, 201825
- Board memberGarrett Lustig Nov 14, 2024 to now26
- Board memberMichael Joseph Driscoll Feb 17, 2022 to now27
- Board memberGilberto Quintero May 5, 2022 to now28
- Board memberMichele Ilene Korfin May 5, 2022 to now29
- Board memberJon L. Giacomin May 11, 2021 to now30
- Board memberPrathyusha Duraibabu Nov 23, 2021 to now31
- Board memberDavid Erani Nov 13, 2020 to Nov 13, 202032
- Board memberRobert Ades Nov 16, 2020 to Nov 16, 202033
- Board memberDavid F. Burgstahler Oct 15, 2018 to May 18, 202134
- Board memberThompson Dean Oct 15, 2018 to May 18, 202134
- Board memberAlan A. Ades Dec 12, 2018 to now35
- Board memberAlbert Erani Dec 12, 2018 to Sep 10, 201935
- Board memberArthur S. Leibowitz Dec 12, 2018 to now36
- Board memberGary S. Gillheeney Dec 12, 2018 to now14
- Board memberGlenn H. Nussdorf Dec 12, 2018 to now37
- Board memberJoshua Alexander Tamaroff Dec 12, 2018 to Feb 18, 202138
- Board memberMaurice Ades Dec 12, 2018 to Dec 12, 201839
- Board memberWayne D. Mackie Dec 12, 2018 to Feb 18, 202140
- Board memberBrian A. Markison Oct 7, 2016 to Dec 12, 201841
- Board memberCharles C. Harwood Jr. Oct 7, 2016 to Dec 12, 201842
- Board memberHakan Bjorklund Oct 7, 2016 to Dec 12, 201843
- Board memberRobert P. O'Neil Oct 7, 2016 to Dec 12, 201844
- General counselLori Freedman Dec 12, 2018 to Feb 24, 202345
- General counselBenjamin Silbert Oct 7, 2016 to Oct 7, 201646
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Executive OfficerDavid C. Francisco named Nov 27, 202447
Former names
- Avista Healthcare Public Acquisition Corp.Dec 18, 2015 to Dec 10, 20183
Timeline
Filings
296 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 39 major events, 181 insider forms, 22 large holders, 1 private raises, 31 other. The latest 20:
- Aug 6, 20268-K EDGAR
- Aug 6, 2026424B5 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jun 16, 20268-K EDGAR
- May 7, 202610-Q EDGAR
- May 7, 20268-K EDGAR
- Apr 30, 2026ARS EDGAR
- Apr 30, 2026DEF 14A EDGAR
- Apr 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 11, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 11, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Mar 3, 20264/A AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
69 open-market trades by officers, directors and large owners since October 2021: 22 buys and 47 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Leibowitz Arthur SDirector | Buy | 5,000 | $2.68 | $13.4K | Form 4 |
| Mar 9, 2026 | Driscoll Michael JosephDirector | Buy | 10,000 | $2.67 | $26.7K | Form 4 |
| Dec 16, 2025 | NUSSDORF GLENN HDirector | Sale | 200,000 | $5.14 | $1.0M | Form 4 |
| Nov 26, 2025 | NUSSDORF GLENN HDirector | Sale | 187,957 | $5.29 | $994.3K | Form 4 |
| Nov 25, 2025 | NUSSDORF GLENN HDirector | Sale | 12,043 | $5.30 | $63.8K | Form 4 |
| Nov 24, 2025 | NUSSDORF GLENN HDirector | Sale | 100,000 | $5.34 | $534.0K | Form 4 |
| Jun 10, 2025 | NUSSDORF GLENN HDirector | Sale | 18,620 | $3.56 | $66.3K | Form 4 |
| Jun 9, 2025 | NUSSDORF GLENN HDirector | Sale | 4,156 | $3.50 | $14.5K | Form 4 |
| Jun 6, 2025 | Freedman LoriChief Admin. and Legal Officer | Buy | 9,022 | $2.99 | $27.0K | Form 4 |
| Jun 5, 2025 | Freedman LoriChief Admin. and Legal Officer | Buy | 142,379 | $2.91 | $414.3K | Form 4 |
| Jun 4, 2025 | Freedman LoriChief Admin. and Legal Officer | Buy | 100,863 | $2.82 | $284.4K | Form 4 |
| May 15, 2025 | NUSSDORF GLENN HDirector | Buy | 107,494 | $2.99 | $321.4K | Form 4 |
| May 14, 2025 | NUSSDORF GLENN HDirector | Buy | 251,001 | $3.09 | $775.6K | Form 4 |
| Mar 4, 2025 | Driscoll Michael JosephDirector | Sale | 25,000 | $5.10 | $127.5K | Form 4 |
| Dec 16, 2024 | Gillheeney Gary S.President and CEO | Sale | 5,585 | $3.49 | $19.5K | Form 4 |
| Dec 13, 2024 | Gillheeney Gary S.President and CEO | Sale | 55,615 | $3.36 | $186.9K | Form 4 |
| Dec 12, 2024 | Gillheeney Gary S.President and CEO | Sale | 43,359 | $3.55 | $153.9K | Form 4 |
| Dec 11, 2024 | Gillheeney Gary S.President and CEO | Sale | 157,448 | $3.64 | $573.1K | Form 4 |
| Dec 10, 2024 | Gillheeney Gary S.President and CEO | Sale | 58,525 | $3.64 | $213.0K | Form 4 |
| Dec 9, 2024 | Gillheeney Gary S.President and CEO | Sale | 41,052 | $3.52 | $144.5K | Form 4 |
All 69 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- First Light Asset Management, LLCSCHEDULE 13G/A, 2 filings Aug 14, 2025 to Feb 17, 202648
- Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 6 filings Oct 13, 2022 to Feb 12, 202649
- Glenn H. NussdorfSCHEDULE 13D/A, 1 filing Nov 3, 202550
- Alan A. AdesSCHEDULE 13D/A, 6 filings Dec 17, 2021 to Jun 26, 202551
- Avista Healthcare Partners III, L.P.SC 13D, 1 filing Nov 19, 202452
- Morgan StanleySC 13G, 1 filing Feb 9, 202453
- James E. FlynnSC 13G/A, 2 filings Feb 11, 2022 to Feb 10, 202354
Money raised
Private offerings the company reported to the SEC on Form D.
- Nov 12, 2024Raised $130 million in a private offering of equity Form D: 2 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Morgan Stanley | 11,721,609 | $28.5M | 0.0% | +104,814 |
| Soleus Capital Management, L.P. | 10,140,951 | $24.6M | 0.8% | +55,000 |
| BlackRock, Inc. | 7,249,528 | $17.6M | 0.0% | +2,349,777 |
| Assenagon Asset Management S.A. | 3,935,904 | $9.6M | 0.0% | +1,967,952 |
| Dimensional Fund Advisors LP | 3,050,297 | $7.4M | 0.0% | +159,291 |
| Aqr Capital Management LLC | 3,011,753 | $7.3M | 0.0% | +2,130,036 |
| Vanguard Capital Management LLC | 2,905,919 | $7.1M | 0.0% | +5,103 |
| D. E. Shaw & Co., Inc. | 2,888,313 | $7.0M | 0.0% | +590,339 |
| Geode Capital Management, LLC | 1,935,554 | $4.7M | 0.0% | +151,590 |
| Deutsche Bank Ag\ | 1,706,186 | $4.1M | 0.0% | +505 |
| Vanguard Portfolio Management LLC | 1,607,729 | $3.9M | 0.0% | +158,637 |
| State Street Corp | 1,519,955 | $3.7M | 0.0% | −5,153 |
| Renaissance Technologies LLC | 1,017,113 | $2.5M | 0.0% | −51,425 |
| Charles Schwab Investment Management Inc | 905,024 | $2.2M | 0.0% | +25,192 |
| Goldman Sachs Group Inc | 887,399 | $2.2M | 0.0% | +367,049 |
| Citadel Advisors LLC | 867,929 | $2.1M | 0.0% | +323,694 |
| Flax Pond Capital, LLC | 842,682 | $2.0M | 0.7% | +422,591 |
| Jacobs Levy Equity Management, Inc | 692,197 | $1.7M | 0.0% | New |
| Healthcare Of Ontario Pension Plan Trust Fund | 628,700 | $1.5M | 0.0% | New |
| Northern Trust Corp | 584,577 | $1.4M | 0.0% | +30,149 |
| Bank Of America Corp /de/ | 563,048 | $1.4M | 0.0% | +14,786 |
| Sphera Funds Management Ltd. | 550,000 | $1.3M | 0.2% | No change |
| Norges Bank | 530,900 | $1.3M | 0.0% | New |
| Vanguard Fiduciary Trust Co | 495,363 | $1.2M | 0.0% | −3,089 |
| UBS Group AG | 358,708 | $871.7K | 0.0% | +151,180 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARDavid F. Burgstahler, Officer
- 23
- 24SEC EDGARBrian Grow, Chief Commercial Officer
- 25
- 26SEC EDGARGarrett Lustig, Board member
- 27
- 28SEC EDGARGilberto Quintero, Board member
- 29SEC EDGARMichele Ilene Korfin, Board member
- 30SEC EDGARJon L. Giacomin, Board member
- 31SEC EDGARPrathyusha Duraibabu, Board member
- 32SEC EDGARDavid Erani, Board member
- 33SEC EDGARRobert Ades, Board member
- 34SEC EDGARDavid F. Burgstahler, Board member
- 35SEC EDGARAlan A. Ades, Board member
- 36SEC EDGARArthur S. Leibowitz, Board member
- 37SEC EDGARGlenn H. Nussdorf, Board member
- 38
- 39SEC EDGARMaurice Ades, Board member
- 40SEC EDGARWayne D. Mackie, Board member
- 41SEC EDGARBrian A. Markison, Board member
- 42SEC EDGARCharles C. Harwood Jr., Board member
- 43SEC EDGARHakan Bjorklund, Board member
- 44SEC EDGARRobert P. O'Neil, Board member
- 45SEC EDGARLori Freedman, General counsel
- 46SEC EDGARBenjamin Silbert, General counsel
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54